We're setting ourselves up for incredible. For ruining the company, ruining the prospects of the product going forward. So there are tremendous disincentives to companies to try to help where they can. Because we haven't mentioned this yet, but right now we're talking about the disincentives for maybe having the FDA really stop the approval process. We haven't even talked about trial lawyers. Yeah. And the liability issues here as well, which. You know, Laura, I want to kind of go, go back to you. (25:46–25:56)
CLAIM
Asserts that there are disincentives related to the FDA stopping the drug approval process.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
